Summary
Introduction
The term motor neuron disease encompasses a variety of neurodegenerative diseases of which amyotrophic lateral sclerosis (ALS) is the most common. Since the work of Charcot and Joffroy (1869) , ALS has come to define a fatal, progressive disease involving loss of motor neurons in the cerebral cortex, degeneration of the descending motor pathways to the motor nuclei in the brainstem and spinal cord, and loss of the motor neurons in these nuclei. This is clinically manifested by hyperreflexia, clonus, spasticity and progressive paresis and wasting of the skeletal muscles with fasciculations relatively sparing the oculomotor and sphincter muscles (Brooks, 1994) .
Most epidemiological studies have found that~35% of cases begin in the lower limbs, 30-35% in the upper Number of patients with a missense or non-sense SOD mutation is shown in parenthesis. * Includes in addition to patients with ALS also patients with Kennedy's Syndrome (11), primary lateral sclerosis (four), motor neuron disease-parkinsonism and/or motor neuron disease-dementia complex (seven), monomelic motor neuron disease (one) and Hiryama's disease (one). None of these carried a CuZn-SOD mutation. † Of the nine sporadic cases with a SOD mutation found in Finland, seven were homozygous and two were heterozygous for the Asp90Ala mutation. SALS ϭ sporadic ALS; FALS ϭ familial ALS.
extremities, 3-5% have truncal onset and in 18-33% the disease starts as a progressive bulbar palsy (PBP) (Kristensen and Melgaard, 1977; Rosati et al., 1977; Forsgren et al., 1983; Gubbay et al., 1985; Haverkamp et al., 1995) . It has been disputed whether patients with PBP constitute a nosologic entity distinct from patients with limb and truncal onset. In 1830, Sir Charles Bell described a patient with paresis of the tongue and limbs, in 1848-50 Aran detailed adult patients with asymmetric limb onset, progressive wasting and paresis, and in 1860 Duchenne described patients with 'progressive muscular paralysis of the tongue, palate and lips'. Finally, Charcot (1881) applied the name amyotrophic lateral sclerosis to the motor neuron syndrome with lesions of both the upper and lower motor neurons, with the syndromes of progressive muscular atrophy and PBP being considered as separate entities. Supporting the idea that PBP may be a separate entity is a female preponderance and significantly higher mean age of onset compared with patients with onset in other parts of the body (Kristensen and Melgaard, 1977; Rosati et al., 1977; Forsgren et al., 1983; Haverkamp et al., 1995) . Since the observation in 1993 that some familial cases of ALS are associated with mutations in the gene encoding the free radical scavenging enzyme CuZn-superoxide dismutase (CuZn-SOD) (Rosen et al.,1993) , we have analysed blood samples from Scandinavian patients with motor neuron disease for mutations in the CuZn-SOD gene. We present here the results of our detailed phenotypic and genealogical studies of the patients with different CuZn-SOD mutations.
Patients and methods
Blood samples were collected according to a standardized protocol (Andersen et al., 1995) , with informed consent, from patients with adult-onset motor neuron disease living in Denmark, Finland, Norway and Sweden. All samples were screened for mutations in the CuZn-SOD gene using a polymerase chain reaction (PCR) single-stranded conformational polymorphism (SSCP) technique as described previously (Andersen et al., 1995) . All five exons of the CuZn-SOD gene were analysed. In samples with an abnormal SSCP band pattern, the existence of a mutation was confirmed by DNA sequence analysis performed on plasmid-cloned PCR products. At least two clones showing the same PCR-SSCP bands as the genomic DNA from the patient were sequenced. With informed consent, samples were collected from relatives of the patients with a CuZn-SOD mutation. These samples were analysed either by PCR-SSCP or by a restriction enzyme test, as the Asp90Ala mutation introduces a new site for the restriction enzyme Fnu4H1 (Andersen et al., 1996) .
The SSCP technique is reported to have a sensitivity of 80-90% (Sheffield et al., 1993) . To increase the likelihood of finding patients with mutations, we also measured the CuZn-SOD activity in erythrocytes as described previously (Marklund, 1976 (Marklund, , 1985 . The assay was performed directly on haemolysates without prior precipitation of haemoglobin (Hb), and the SOD enzyme activity was expressed in U/mg Hb.
The case records of the patients with a CuZn-SOD mutation were scrutinized, and the family history and pedigree were documented by interviewing patients and relatives, and by inspection of official records. The study received approval from the ethical committees of the universities of Copenhagen, Denmark; Oulu, Finland and Umeå, Sweden.
Results
From the spring of 1993 to the end of 1996 we collected a total of 451 samples from approximately a quarter of all adult motor neuron disease cases in the four countries during that period. Of the analysed samples from ALS cases (Table  1) , 355 were sporadic ALS (SALS) cases and 72 (16.9%) were familial ALS (FALS) cases from 51 families. A CuZn-SOD mutation was found in 44 (10.3%) samples. Three (AAC139→AAT, GCT140→GCA, CAA153→CAG) were silent mutations (mutations not causing a change in the amino acid sequence of the final polypeptide), each found in one ALS patient. In 41 patients five different mutations were found, of which four were missense mutations (replacement of one amino acid with another amino acid) and one a nonsense mutation (replacement of an amino acid codon with a stop codon), and can be presumed to be disease causative.
The Ala4Val (A4V) mutation
The Ala4Val CuZn-SOD mutation was found in a large family originating in central Sweden. Part of the pedigree is shown in Fig. 1A .
II-2 developed a rapidly progressive motor neuron disease at the age of 55 years, beginning in the hand and soon involving the whole upper left extremity with initial shoulder pain. Death came 11 months after onset of the first symptom.
III-4 developed suddenly, at the age of 68 years, ripplings in the left facial muscles and progressive dysarthria followed by dysphagia and a progressive left facial nerve palsy. Ten months after onset and 1 month before her death, she had severe dysarthria, tongue atrophy with fasciculations, atrophic paralytic facial muscles, paralysis of the left recurrent laryngeal nerve, severely paretic and wasted upper extremities, especially distally. There was only slight paresis of the lower limbs. The deep tendon reflexes were very weak or absent in all four limbs. The Babinski response could not be elicited. Cutaneous sensation and neuro-ophtalmological examination were normal. EMG showed neurogenic atrophy in all four limbs.
III-6 noticed right foot dorsal flexion paresis at the age of 50 years. Six months later she had a severe flaccid paresis of the right leg, apparently without the left leg or of the upper extremities being affected. Cutaneous sensation was intact. No fasciculations were registered, and no signs of upper motor neuron involvement. Spinal myelography revealed no significant abnormalities. EMG showed neurogenic atrophy. Ten months from onset the patient had a flaccid paraparesis, and distal paresis and wasting in the right arm. The left arm was unaffected until 3 months before her death, 17 months after onset of the first symptom. Autopsy confirmed the diagnosis.
In IV-4, illness began at the age of 61 years with sudden disturbed motor control of his right hand. A progressive stroke was suspected, and he was initially treated with infusion of heparin but a CT-scan of the brain was normal. The initial examination revealed intact cranial nerves, fasciculations on both shoulders and on the right thigh, a slight paresis of shoulder elevators and paresis of the right hand but no paresis in the lower limbs. The right brachioradial reflex was absent. The other deep tendon reflexes were normal. Decreased pain sensation was noted in the right forearm and hand. Within 1 month dysphagia developed and the left arm became paretic. Three months after onset, dysarthria was noted. On re-examination, the upper extremities showed a flaccid paresis with distal wasting and paresis of the neck extensors, lingual fasciculations, diminished or absent deep tendon reflexes in the arms, predominantly on the right side, but reflexes in the legs were normal. Sensation of vibration was normal. EMG revealed neurogenic changes in the tongue and in both arms but not in the legs. Five months after onset, paresis developed in the right leg, and the patellar reflexes were absent. The right Achilles reflex was weak while that on the left was brisk.
Six months after onset the patient complained of dyspnoea and aphagia, and a gastrostomy was performed. At the time of his death, Ͻ8 months after onset of the first symptom, the patient could still walk but the arms and tongue were wasted; the left Achilles reflex could be elicited but otherwise there was areflexia. As in all earlier examinations, the Babinski sign could not be elicited. Oculomotor function and sphincter functions remained intact.
SSCP analysis on lymphocytes obtained from IV-4 revealed an aberrant band pattern in exon 1. Subsequent nucleotide sequencing revealed a heterozygous missense C to T exchange in base pair position 94 in codon 4, resulting in an alanin to valin (Ala4Val; A4V) substitution. Samples from eight family members with a 50% risk of having inherited the mutant allele were also analysed, and two were found to have inherited the mutation, including an off-spring of III-6. They are 56 and 54 years of age, and do not show symptoms of motor neuron disease. The enzyme activity in the three individuals with the Ala4Val mutation was found to be decreased to~50% (22.9, 23.3 and 26.0 U/mg Hb) of control subjects ( Table 2 ).
The Val14Gly (V14G) mutation
The Val14Gly CuZn-SOD mutation was found in a family whose paternal line originates in central Sweden and the maternal line in Finland. The patient is the only known case of motor neuron disease in his family and he was considered a SALS case. The grandparents all lived to an advanced age and died rather suddenly. The father died of myocardial infarction at the age of 51 years, and the mother shows no symptoms of motor neuron disease at the age of 68 years. A sister is healthy at the age of 40 years.
The patient developed a sense of fatigue in both legs at the age of 39 years. Some months later, lower back fatigue and episodes of severe neuralgic pain in the hips began. Later he noted stiff calves and muscle twitches in both legs. In the ensuing months he had unprovoked episodes of chilliness of up to 3-4 h duration. Initially, paresis developed distally in the legs, but it soon ascended to the thighs. Six months after noticing fatigue he needed to walk with the aid of a stick. A spinal cord MRI scan was unremarkable, as was a spinal fluid examination, except that the protein content was raised to 900 mg/l. EMG, 7 months from onset, revealed neurogenic changes in the lower extremities only. Motor and sensory conduction studies were normal. Repeated neurological examinations revealed involvement of both lower and upper motor neuron systems, but Babinski signs were not found on any examination. After 10 months, paresis appeared first in the left arm and later in the right arm, and progressive urgency of micturition also developed. Sixteen months from the initial symptoms, a reduced sense of vibration was noted in both feet, otherwise sensibility has remained intact. The patient is now severely tetraparetic with dysphagia and dysphonia, but no dysarthria. The patient has not shown mental impairment or affective lability.
Analysis of a blood sample from the patient showed a reduced CuZn-SOD activity of 30.3 U/mg Hb in erythrocytes (control subjects 52.8 Ϯ 5.86 U/mg Hb, n ϭ 96) but the SSCP analysis only revealed a faint, easily overlooked, aberrant band in exon 1 ( Fig. 2A ) the SSCPs for exons 2-5 being normal. Nucleotide sequencing of exon 1 revealed a heterozygous missense T to G exchange in position 124 in codon 14, resulting in a valin to glycin (Val14Gly; V14G) substitution (Fig. 2B ). This example shows that analysis of erythrocyte SOD activity in addition to screening by PCR-SSCP increases the likelihood of detecting CuZn-SOD mutations.
The Asp76Tyr (D76Y) mutation
Two cases of motor neuron disease have been found in this Danish family with the Asp76Tyr mutation (see Fig. 1B ).
I-1 and I-2 died of unknown causes aged 57 and 47 years, respectively. They raised four children, of whom II-1 died at the age of 60 years of a heart disease, II-2 at the age of 52 years (unknown cause) and II-3 at the age of 77 years of a stroke. None of them had children. Born in 1868, II-4 enjoyed a healthy life until, at the age of 67 years, he complained of pharyngeal irritation and copious phlegm, recovering completely within a few weeks. The sense of irritation in the pharynx returned~6 months later, and he soon developed dysphonia and dysphagia causing drooling. He had no complaints about the extremities. Physical examination the following month revealed no signs of infection, but the deep tendon reflexes in the extremities were very brisk. During the following months dysarthria developed and the dysphonia progressed, but the patient could still communicate by writing. His personality changed. He became self-centred, stubborn, with affective lability but no symptoms of dementia. Dyspnoea developed, and shortly before his death~15 months after the first pharyngeal symptoms, it was noted that he had difficulties in walking, particularly with the right leg. Pupil and eye movements were normal, the patient could not Location of onset: B ϭ bulbar; UE ϭ upper extremity; LE ϭ lower extremity; T ϭ truncal (none found in this study). * Seven of them are in their twenties or thirties (children of homozygous patients married to heterozygous spouses). † An Asp90Ala heterozygous sister of one of the two cases with sporadic PBP. Additional 115 Asp90Ala heterozygous individual blood-relatives of the Asp90Ala homozygous patients were also found; none of these have developed motor neuron disease (mean age 56 Ϯ 15 years). ‡ The CuZn-SOD activity in 96 blood relatives without a CuZn-SOD mutation was 52.8 Ϯ 86 U/mg Hb.
Fig. 1
Pedigrees of the families with the Ala4Val (A), Asp76Tyr (B) and Gly127insTGGG (C) mutations. Pedigrees of families with the Asp90Ala mutation have been published earlier (Andersen et al., 1995 (Andersen et al., , 1996 . The fates of II-4-11 in the Ala4Val family are unknown. Individuals are indicated by generations and pedigree numbers. Circle ϭ female; squareϭ male; diamond ϭ unspecified sex; filled symbols ϭ affected; partly filled symbol ϭ possible affected (unconfirmed); open symbols ϭ unaffected; symbols with horizontal lines ϭ dementia; oblique line ϭ deceased individual; arrow ϭ index patient. Minor changes have been made to the pedigrees for confidentiality.
whistle and his tongue was atrophic with 'fibrillations'. Fibrillations were not found in the extremities. The abdominal reflexes were absent. The musculature in the extremities was weak and wasted with brisk tendon reflexes in all four extremities mainly on the right side, and clonus was noted in both ankles. The Babinski sign was found on the left side. No tremor was found, and cutaneous sensation was intact. IV-5, the grandchild of II-4, noted instability of his right ankle at the age of 49 years. The following year he complained of right knee pain and of being unable to stand on the tip of his right foot. An examination 1 year later revealed intact cranial nerves and upper extremities. Extensive wasting was found only in the right lower limb affecting both the extensor and flexor muscles, and being most severe distally. No paresis was found in the left leg. No fasciculations were found. The patellar reflexes were bilaterally brisk, the right more than the left. The Achilles reflex could not be evoked on the right side but was brisk on the left side. The plantar response on the right side was extensor, but normal on the left. The abdominal reflexes were present bilaterally. Cutaneous sensibility and sphincter functions were found intact. Signs of ataxia were not found on this or later examinations. A spinal fluid examination was unremarkable as was a spinal myelography. EMG of the right tibial anterior muscle showed neurogenic changes. Motor and sensory nerve conduction studies were normal.
Three years after onset in the right leg he experienced instability and later weakness starting distally in the left leg.
The disease progressed with slowly ascending paresis. Five years from onset, he required a walking stick. At 6 years he had developed a complete drop-foot on the right side, and after 7 years he first experienced symptoms in the upper extremities in the form of slowly progressive paresis and wasting of the small muscles of the right hand. Twelve years after onset, he could no longer walk or stand on his feet. The same year an insulin-dependent diabetes mellitus was diagnosed. EMG performed 13 years after onset showed the classical signs of neurogenic lesions in all four limbs. A physical examination found no signs of cognitive disturbance and the cranial nerves were intact. The patient was severely tetraparetic with extensive muscular wasting mainly distally and on the right side of the body. There was surprising strength in the shoulder muscles. The deep tendon reflexes were absent, plantar reflexes were 'normal', and cutaneous sensation and proprioception were intact. The following year dysphagia developed. An examination revealed slight paresis and atrophy of the tongue with fasciculations, but the pharyngeal reflexes were normal. Since then, dysphonia and dyspnoea have appeared but the patient still lives at home 15 years after onset of the first symptom, using an electric wheelchair controlled by his left hand.
His mother, III-4, died at the age of 84 years after having suffered from dementia, allegedly due to arteriosclerosis in the last 6 years of her life. According to available records, her cardinal symptom was progressive loss of memory. No information has been found suggesting that she ever developed signs of affective lability like those of her father. An examination 2 weeks prior to her death showed no paresis or wasting. She died of sepsis a week after a femur amputation.
III-2 and III-5 were both demented with a clinical picture very similar to III-4 and they died aged 77 and 84 years, respectively. They did not show signs or symptoms of motor neuron disease, and none of their six children (aged 45-70 years) had developed neurological symptoms. III-7 died, aged 71 years, of a ruptured aneurysm of the aorta without prior signs of motor neuron disease, and III-11 died at the age of 72 years after suffering from repeated cerebrovascular insults. Neither showed signs of intellectual impairment before death. III-10 is alive without signs of motor neuron disease or dementia. Genealogical studies of the family of III-3 revealed no cases of motor neuron disease among his parents, eight siblings or their children.
SSCP analysis of a sample from IV-5 showed an aberrant band in exon 3 (Fig. 2C) , and nucleotide sequencing revealed the patient to be heterozygous for a missense G to T exchange in position 695 in codon 76 (Fig. 2D ) resulting in an aspartic acid to tyrosin (Asp76Tyr; D76Y) substitution. The mutation was also found in a middle-aged healthy relative of IV-5 (not shown in the pedigree for reasons of confidentiality). III-10 and the children of III-2 and III-5 do not carry the mutation.
The enzyme activity in the two individuals with the Asp76Tyr mutation was found to be decreased to~50% (27.0 and 27.8 U/mg Hb, respectively) of control subjects ( Table 2 ).
The Asp90Ala (D90A) mutation
Of the 451 samples tested, 34 were found to be homozygous for the Asp90Ala CuZn-SOD mutation, which we have earlier reported (Andersen et al., 1995) . Including deceased ALS patients, relatives of the 34 whom we have shown to be homozygous for the Asp90Ala mutation, a total of 44 patients have been found showing a characteristic phenotype with asymmetrical onset distally in the lower extremities with slowly ascending paresis. Details of the phenotype of 36 of these patients have been reported earlier (Andersen et al., 1996) . However, among the additional eight patients, signs of slight ataxia have been noted in four patients. The 44 homozygous patients (10 apparent SALS cases and 34 FALS cases taken from 10 families) were all born in northern Sweden or in Finland. Among their relatives, we have found 115 individuals to be heterozygous for the Asp90Ala mutation as well as 68 individuals without a CuZn-SOD mutation. None of these have demonstrated symptoms of motor neuron disease.
Of the 80 blood samples obtained from cases of sporadic motor neuron disease living in Finland, seven were found to be homozygous (described above) and two heterozygous for the Asp90Ala mutation. These two patients both presented with PBP, the male patient dying Ͻ2 years after disease onset, at the age of 56 years, and the female patient died 3 years after disease onset, at the age of 77 years. A 72-year-old sister of the male patient was also found to be heterozygous for the Asp90Ala mutation. She shows no signs of motor neuron disease. The basis for the existence of adult-onset recessive ALS with patients homozygous for the Asp90Ala CuZn-SOD mutation is a CuZn-SOD polymorphism (Kirjarinta et al. 1969; Beckman, 1973) . The allele frequency in most of Finland is~0.5-1%, but in northern Finland and in northern Sweden frequencies as high as 2.5-2.7% have been found (see Andersen et al., 1996) . The two sporadic cases with PBP both came from northern Finland where the allele frequency is~1%, i.e. 2% of the population in this area should be heterozygous for the Asp90Ala mutation, and it may be a coincident finding.
The enzyme activity of individuals homo-or heterozygous for the Asp90Ala mutation is reduced by~7% in both groups compared with neurological control subjects and bloodrelatives without a CuZn-SOD mutation (Table 2 ; Andersen et al., 1995) .
The Gly127insTGGG mutation
Three definitive cases of motor neuron disease have been found in the Danish family with this mutation (see Fig. 1C ).
I-1 died in 1893, at the age of 46 years, of 'nerve inflammation' and may have had motor neuron disease. II-2 died at the age of 35 years after an abortion, and II-1 died at the age of 92 years of 'old age'. III-2 and III-6 both died at the age of 72 years of myocardial infarction and ventricular cancer, respectively. III-1 and III-7 are both alive (aged 89 and 81 years, respectively) without signs of motor neuron disease.
III-5 developed progressive wasting and paresis at the age of 50 years, starting in the left calf. Examined 1 year later, the patient had a paraparesis. The left Achilles reflex was absent and the right was diminished, the left patellar reflex was weak and the right considered normal. There were no Babinski signs. The upper extremities had normal strength with symmetrically very brisk reflexes. The cranial nerves were intact. Re-examined 9 months later, the patient walked with difficulty and had severe paresis and extensive wasting of both upper extremities. Abundant fasciculations were found all over the body. The tongue was considered normal, but a left-sided paresis of the buccator muscle was found. Cutaneous sensation was normal. The deep tendon reflexes and Babinski signs were absent. EMG showed neurogenic atrophy. Dysphagia developed 3 months prior to her death 30 months after onset.
IV-13 first noticed weakness in the left arm at the age of 59 years. An examination 3 months later revealed intact cranial nerves, paresis of the left shoulder with inablity to lift the left arm above the head. Cutaneous sensation was normal, but the sense of vibration was decreased in the left hand and left foot. The muscle tone was normal. The right upper extremity and the lower extremities had normal strength and showed no atrophy. The deep tendon reflexes were very brisk in all four extremities, a Babinski response was found on the right side only, and there was a tendency for clonus in the left ankle. The abdominal reflexes were present. No fasciculations were noticed at this time. EMG showed neurogenic atrophy with denervation, polyphasia and spontaneous activity with fasciculations. MRI of the cervical spine revealed no significant abnormalities. Six months after first symptom she could no longer rise from a squatting position. Generalized myalgia and cramps appeared. Reexamined 9 months after onset revealed generalized symmetrical hyperreflexia, extensive fasciculations, paresis and wasting of the left arm (more proximal than distal). No paresis in the right arm. Twelve months after onset increased muscle tone was noted in both lower and the upper left extremity, atrophy of the small hand muscles bilaterally, very brisk deep reflexes in the right arm and both legs but only weak reflexes in the left arm. Neither clonus nor the Babinski sign were found on this or later examinations. Fifteen months after onset, the patient could still elevate her shoulders, but the arms were severely paretic. A predominantly left-sided paraparesis and dysphagia developed, but articulation was intact for several months. In the last months of life the patient was severely handicapped with generalized wasting, tetraparalysis and universal areflexia. Bladder function remained intact during the 32-month-long disease period.
IV-16 developed a progressive motor neuron disease similar to his sister IV-13 with the exceptions that the first symptoms were distal paresis in the left lower limb with severe myalgia, and the second limb to be clinically affected was the upper right extremity. He died at the age of 44 years after a disease duration of 41 months.
DNA analysis of samples from IV-13 and IV-16 revealed an insertion of four base pairs TGGG after base pair 1450 in codon 127 causing a frameshift and the introduction of five new amino acids ending with a premature stop codon in position 133. The CuZn-SOD subunit is thereby truncated by 21 amino acids compared with the wild-type polypeptide of 153 amino acids. The genetic details of this mutation is being published (Hansen et al., 1997) . Four of the five siblings of IV-13 and IV-16 (aged 45-67 years) have also inherited the mutation but are without motor neuron disease. The CuZn-SOD activity in erythrocytes was measured in four individuals with the mutation and was found to be decreased to~40% (24.5, 21.1, 19 .1 and 20.1 U/mg Hb) of control subjects (Table 2) .
Discussion
The present study is the first large epidemiological study of the frequency of CuZn-SOD mutations in an unselected population of motor neuron disease patients. A smaller study of 67 ALS patients has been reported earlier from Scotland (Jones et al., 1995) . In the comparatively small motor neuron disease population in Scandinavia (23.3 million inhabitants)
we have found five different CuZn-SOD mutations with novel features:
The phenotypes
Whereas the 44 patients homozygous for Asp90Ala showed a characteristic uniform phenotype with insidious onset, slowly ascending paresis beginning distally in the lower extremities and long survival, patients with the other four mutations showed diverging phenotypes. The four patients with the Ala4Val mutation all had sudden onset (suggesting the existence of some kind of trigger factor) and showed rapid disease progression, but the sites of onset differed. The three patients with Gly127insTGGG exhibited different sites of onset, but the disease progression rate was slower than for the patients with the Ala4Val mutation. In the Asp76Tyr family, one patient had bulbar onset and rapid progression, while his daughter never showed symptoms of motor neuron disease and the grandchild developed a slowly ascending paresis very similar to that of the patients homozygous for Asp90Ala. Strikingly, even on repeated examinations and at different stages of the disease, the patients with Ala4Val only showed signs of lesion to the lower motor neuron system. For the other mutations, signs of lesions to the descending motor pathways were found in all patients except for III-4 (Gly127insTGGG) who only had lower motor neuron signs. None of the patients developed severe spasticity and, judging from published descriptions of patients with other CuZn-SOD mutations, spasticity appears to be uncommon among patients with a CuZn-SOD mutation. The greatest difference among patients with the different mutations is the rate of disease progression; the four patients with the Ala4Val mutation had a mean survival time of only 0.9 years compared with 14.2 years for 15 deceased patients homozygous for Asp90Ala (Table 2) .
Urgency of micturition and/or difficulty initiating urination is a common symptom in patients homozygous for Asp90Ala (Andersen et al., 1996) and was also reported by the single patient with the Val14Gly mutation. Four of the patients with the Asp90Ala mutation exhibited slight ataxia indicating the involvement of the posterior columns and cerebellum. None of the patients with the Ala4Val, Asp76Tyr or Gly127insTGGG mutations had similar findings. A preparetic phase characterized by myalgia, muscle cramps and painful parestheses were only reported consistently by patients homozygous for the Asp90Ala mutation and the single patient with the Val14Gly mutation. The existence of a preparetic phase of months to years duration supports the theory (Swash and Ingram, 1988) that there is a long preclinical period of relative tolerance and compensation. Several patients demonstrated signs and symptoms of autonomic, bladder, cerebellar and/or sensory involvement indicating that in patients with CuZn-SOD mutations the disease is not confined to the voluntary motor system. When present, these features may distinguish patients with a CuZn-SOD mutation from other motor neuron disease patients. (i) Symptoms of myalgia and/or cramps. Increased deep tendon reflexes may be found locally, but there is no wasting, paresis or fasciculation. (ii) Symptoms of 'instability' and/or weakness. The only sign found is that of brisk reflexes not only in the region of complaint but also proximal to it, and perhaps in other, still asymptomatic regions. (iii) Focal, asymmetric paresis develops with some wasting. The deep tendon reflexes in the affected region are diminished or absent. In other regions the reflexes are brisk. Superficial reflexes are intact and the plantar response flexor. (iv) The paresis and wasting progress to include the complete extremity, and the first symptoms appear in another region. In the primary affected extremity, the reflexes will be diminished or absent, in the other regions the deep tendon reflexes will be brisk. Fasciculations appear not only in the primary affected region but also in nearby myotomes. The abdominal reflexes are absent, and the plantar responses may be extensor. (v) Generalized wasting with tetraparesis with diminished or, more likely, areflexia in most regions. No plantar response can be elicited.
Involvement of the posterior columns and spinocerebellar tracts is a common pathoanatomical finding in ALS patients though it is clinically most often silent (Engel et al., 1959; Hirano et al., 1967; Averback et al., 1982) . Autopsies have revealed, in addition to loss of anterior horn cells, involvement of the posterior columns and spinocerebellar tracts in patients with the Ala4Thr , Ile113Thr (Orrell et al., 1995b) , Glu100Gly (Ince et al., 1996) and Ala4Val (Shibata et al., 1996) mutations. Thus, patients with the Ala4Val, Val14Gly and Gly127insTGGG mutations conform to Type II and patients homozygous for the Asp90Ala mutation conform to Type III according to the FALS classification of Horton et al. (1976) .
The patients had asymmetrical and focal onset of paresis and wasting as dominant symptoms in common. Development of new symptoms and signs followed a stereotyped pattern (Table 3) . With disease progression, the signs of lesion to the descending motor pathways may be masked by advanced muscular atrophy. Also in common was the absence of bedsores. Only two patients developed small bedsores after long immobilization, supporting the idea that the skin is involved in the ALS disease process (Kolde et al., 1996) .
Dominantly and recessively inherited ALS with the Asp90Ala mutation
The relatively uniform phenotype of the 44 patients homozygous for the Asp90Ala mutation is noteworthy. Our earlier finding of two patients with PBP heterozygous for the Asp90Ala mutation suggests that either they were coincidental carriers of the Asp90Ala allele or that there are other factors shaping the phenotype of individuals with a CuZn-SOD mutation. Recently, five patients of non-Scandinavian descent heterozygous for the Asp90Ala mutation have been found in Belgium with variable phenotypes (Robberecht et al., 1996) , none having a phenotype similar to our earlier reported homo-and heterozygous patients. Also, a SALS case heterozygous for the Asp90Ala mutation has been found in England (Jackson et al., 1996) , a North American Caucasian FALS family homozygous for the Asp90Ala mutation with rapidly progressing disease and ataxia has recently been reported (Kaplan et al., 1996) , and two FALS families, one homozygous the other heterozygous for the Asp90Ala mutation, have been found in different locations in France (Dr W. Camu, personal communication). These findings suggest that, in the area where the Asp90Ala polymorphism exists in Finland and northern Sweden, there may also be an unknown factor reducing the susceptibility of individuals with the Asp90Ala mutation to the deleterious effect of the mutated CuZn-SOD molecule; thus only individuals homozygous for the mutation develop ALS. This resistance factor may also account for Scandinavian Asp90Ala patients having a far more homogeneous phenotype compared with patients with the Asp90Ala mutation from other locations, or, indeed, compared with nearly all other reported CuZn-SOD mutations. This resistance factor may also contribute to the very long disease duration in Scandinavian patients homozygous for the Asp90Ala mutation. Several of these patients moved before onset of ALS to other parts of Sweden, where they lived under different conditions, but the phenotype of the patients who moved is similar to patients who remained, suggesting this tentative protective factor may be of genetic origin or from influences early in life, or both. This idea is supported by the fact that the Finnish population is very homogeneous and genetically different from most other populations of Europe (Nevanlinna, 1972) .
Sporadic cases and disease penetrance
The Val14Gly was found in an apparently sporadic case. Genealogical studies failed to find any other family members with a neurodegenerative disease. The widespread Asp90Ala polymorphism in Finland and northern Sweden associated with ALS in homozygous form makes it possible that apparently sporadic cases have a genetic aetiology. Seven of the 80 sporadic motor neuron disease cases analysed in Finland were homozygous for the Asp90Ala mutation, and a further three apparently sporadic cases were found in Sweden (Table 1 ). Since we have found Asp90Ala homozygous patients with late onset of ALS, we cannot exclude the possibility that homozygosity for Asp90Ala mutation may be associated with complete penetrance for ALS; it then becomes a matter of the patient surviving other diseases.
The other three mutations found show dominant inheritance, the Ala4Val with high penetrance, but the pedigree is too small to conclude that the penetrance is complete. In the family with the Gly127insTGGG mutation, III-4 was considered a SALS case because her mother died early, at the age of 35 years, without symptoms of ALS. Four asymptomatic carriers of the Gly127insTGGG allele were found in this family aged between 45 and 67 years. The sample is too small to assess whether or not the Gly127insTGGG mutation is associated with decreased penetrance.
The ALS patient with the Asp76Tyr mutation was considered sporadic until the discovery of reduced CuZn-SOD activity and subsequently the Asp76Tyr mutation prompted us to investigate the family history. No sample is available from II-4 to prove that he did carry Asp76Tyr. The possibility exists that his grandchild IV-5 may be a new mutation and that the occurrence of motor neuron disease in II-4 and IV-5 may be independent events. In the case records of II-4, it is stated that no other cases are known in the family. None of his six children developed motor neuron disease. The only living child is III-10 and she does not carry the Asp76Tyr allele. III-2, -4 and -5 all developed a similar demential disease in their seventies, with progressive loss of memory as the cardinal symptom. We suggest that the Val14Gly and Asp76Tyr mutations may be associated with decreased penetrance as was found previously in cases with the Ile113Thr mutation in Australia (Suthers et al., 1994) , Scotland (Jones et al., 1995) and North America (Deng et al., 1995) , and in one case each with the Glu21Lys (Jones et al., 1994a) , Asp101Asn (Jones et al., 1994b) and Gly16Ser (Kawamata et al., 1995) .
The possibility exists that Asp76Tyr may in fact have complete penetrance and that the dementia found in III-2, -4 and -5 may be another manifestation of the mutation. A few families where different generations have developed either motor neuron disease or dementia have been reported (Hudson, 1981; Frecker et al., 1990; Gunnarson et al., 1991) . However, no biological material is available from any of these three. None of the living children of III-2 and III-5 carries the Asp76Tyr mutation. The present data do not allow the conclusion that Asp76Tyr is associated with dementia. We reported earlier that Asp90Ala is not associated with dementia (Andersen et al., 1996) .
The Ala4Val mutation
The Ala4Val mutation is the most commonly found CuZn-SOD mutation associated with motor neuron disease, accounting for about a fifth of all SOD-associated FALS families in the USA , but has not previously been reported outside North America. The phenotype of the American patients ) is similar to the phenotype in the Swedish family with the Ala4Val mutation showing only symptoms and signs of a rapidly progressive lower motor neuron disease, but autopsy revealed degeneration of the corticospinal tracts in three of the American cases (Shibata et al., 1996) . Since members of the Swedish family are known to have emigrated to North America, it is possible that the American patients are descendants of Swedish emigrants (1.2 million Swedes emigrated to North America in the last century).
Progressive bulbar palsy
PBP appears to be a very rare phenotype in patients with a CuZn-SOD mutation (Radunovic and Leigh, 1996) . We reported two cases of PBP heterozygous for the Asp90Ala mutation (Andersen et al., 1995) , but due to the high frequency of the Asp90Ala allele in northern Finland these findings may have been coincidental. In the present study, the detailed case records leave no doubt that III-4 in the Ala4Val-family and II-4 of the Asp76Tyr-family both presented with PBP, even though samples are not available to prove that they actually did carry a SOD mutation. III-4 (Ala4Val) is an obligate gene carrier. The present report is the first of an Ala4Val patient with PBP. Of the 57 CuZn-SOD mutations reported in ALS patients (Fig. 3) , PBP has been reported only in a Japanese family with the Val148Ile mutation (Ikeda et al., 1995a) , and a German family with the Ile151Thr mutation (Kostrzewa et al., 1996) . This is surprising, since epidemiological studies show that PBP comprises~18-33% of all ALS cases (Kristensen and Melgaard, 1977; Rosati et al., 1977; Forsgren et al., 1983; Gubbay et al., 1985; Haverkamp et al., 1995) . Of the ALS samples analysed in this study, 19.4% were from patients with PBP.
The tendency of patients with a CuZn-SOD mutation to develop the first symptom in the neurons innervating the limbs rather than the neurons innervating the labio-glossopharyngeal muscles is striking and accords with findings in mice carrying different ALS-associated human CuZn-SOD mutations inserted into the genome (Gurney et al., 1994; Ripps et al., 1995; Wong et al., 1995) . The neurons innervating the limbs, particularly the lower limbs, are also the neurons with the longest axons and therefore the ones with the largest metabolic demand and should be more susceptible to interference with the axonal transportation mechanism.
The CuZn-SOD mutations
While the Ala4Val (Deng et al., 1993) , Asp90Ala (Andersen et al., 1995) and Gly127insTGGG (Hansen et al., 1997) mutations have all been reported previously, the Val14Gly and Asp76Tyr mutations are novel discoveries. Fifty-seven different mutations at 42 codons of the 153 codons defining the CuZn-SOD subunit (the CuZn-SOD enzyme is a dimer consisting of two identical subunits) have now been reported in cases with ALS (Fig. 3) . Of the mutations, 10 occur among the 23 codons of exon 1, seven among the 32 codons of exon 2, 20 among the 39 codons of exon 4, and 17 among the 35 codons of exon 5. Two mutations are located in the intron between exon 4 and 5, leading to changes in splice sites and the final sequence of the polypeptide. The lack of association between the genotype and enzyme activity on one hand and the phenotype and prognosis with the different mutations on the other (Table 2) , supports the theory that the various CuZn-SOD mutations cause ALS by the mutated CuZn-SOD protein gaining an adverse property, rather than by loss of enzyme activity (Borchelt et al., 1994; Esteban et al., 1994; Gurney et al., 1994; Tsuda et al., 1994; Andersen et al., 1995; Bowling et al., 1995; Rabizadeh et al., 1995;  reviewed by Radunovic and Leigh, 1996) . The uneven distribution of mutations may reflect the differences in importance of changes in amino acid residues in different regions in causing the gain of this toxic property. It may also partially reflect a difference in mutation rates in different parts of the gene. Indeed, in our study with screening of all five exons with SSCP in ALS cases, we have found three silent mutations in exon 5, which may be a mutation hotspot. It should be noted that the GCT140→GCA silent mutation was found in a FALS case and also in the 40-yearold healthy son of a deceased FALS patient from the same family (pedigree not shown). This silent mutation was reported earlier (Hosler et al., 1996) . We cannot exclude the possibility that these silent mutations are involved in the pathogenesis of the disease.
Val14 has previously been found mutated to a Met in cases of FALS (Deng et al., 1995) . It forms part of a cluster of hydrophobic packing interactions closing off one end of the β-barrel of the CuZn-SOD molecule (Deng et al., 1995) . It is highly conserved but not sequence-invariant, suggesting that its interactions are of structural importance. It has tight interactions with Ile35, Leu38, His43 and Leu144, the latter three being involved in mutations associated with ALS. The remaining 50% of SOD activity in erythrocytes of the heterozygous Val14Gly patient is indicative of a reduced stability caused by the mutation.
The Asp76Tyr mutation is the first reported among the 24 codons of exon 3. The negatively charged Asp76 is located in the 'Zn sub-loop' (Getzoff et al., 1989) on the surface Fig. 3 Schematic illustration of the reported mutations in the five exons of the CuZn-SOD gene. The numbers on the left show the positions of the silent mutations; on the right side of the column the positions of the mutated loci with the amino acid residues are shown in the three-letter code. The black sections between the exons illustrate the four introns of the CuZn-SOD gene, with the two mutations with base pair change (bp) shown in intron 4. The residue numbers of the first and last amino acids in each exon are shown in small numbers inside the boxes. * Indicates the mutations described in this report. The other data were compiled from Aoki et al., 1993; Deng et al., 1993 Deng et al., , 1995 Rosen et al., 1993; Elshafey et al., 1994; Esteban et al., 1994; Hirano et al., 1994; Jones et al., 1994 a, b; Kostrzewa et al., 1994; Nakano et al., 1994; Pramatarova et al., 1994 Pramatarova et al., , 1995 Andersen et al., 1995; Aoki et al., 1995; Calder et al., 1995; Enayat et al., 1995; Ikeda et al., 1995a, b; Kawamata et al., 1995; Moulard et al., 1995; Nakashima et al., 1995; Orrell et al., 1995a Orrell et al., , b, 1997 Sapp et al., 1995; Yulug et al., 1995; Hosler et al., 1996; Kostrzewa et al., 1996; Morita et al., 1996; Robberecht et al., 1996; Siddique et al., 1996; Bereznai et al., 1997; Hansen et al., 1997; Watanabe et al., 1997. of the molecule opposite to the dimer interface. It forms electrostatic contacts with the positively charged Lys128 in the 'electrostatic channel' loop (Getzoff et al., 1989) . This interaction may be important for the joining of these two loops, which together form the active site channel (Tainer et al., 1982) . Asp76 shows strong evolutionary conservation (Bordo et al., 1994) and at position 128 the positively charged amino acids Lys or Arg are found in most species (Bordo et al., 1994) , suggesting the importance of this interaction. Replacement with the neutral bulky Tyr is likely to destabilize this part of the molecule, which may explain the mere 50% remaining SOD activity in erythrocytes from the heterozygous patient.
Conclusion
The various CuZn-SOD mutations apparently cause motor neuron degeneration by an acquired toxic property. The reason for the high susceptibility of motor neurons to the reputed adverse property of this ubiquitously expressed protein is not known. However, it is likely that the various mutations cause motor neuron damage by essentially the same mechanism even though the disease phenotype varies among the mutations for mode, location and age of onset, and particularly rate of disease progression. Remarkably, early onset is not related to rapid rate of progression. Though PBP is rare among patients with CuZn-SOD mutations, we conclude that patients with CuZn-SOD mutations can manifest different motor neuron disease phenotypes fulfilling all the clinical depictions of Bell, Aran, Duchenne and Charcot.
